Hyperphosphorylation of PP2A in colorectal cancer and the potential therapeutic value showed by its forskolin-induced dephosphorylation and activation

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1842, Issue 9, 2014, Pages 1823-1829

  Cristóbal, Ion ^a   Rincón, Raúl ^a   Manso, Rebeca ^b   Madoz Gúrpide, Juan ^b   Caramés, Cristina ^a   del Puerto Nevado, Laura ^a   Rojo, Federico ^b   García Foncillas, Jesús ^a  

^a UAM)   (Spain)

^b HOSPITAL UNIVERSITARIO FUNDACIÓN JIMÉNEZ DÍAZ   (Spain)

Author keywords

5 Fluorouracil; Colorectal cancer; Forskolin; Oxaliplatin; PP2A C phosphorylation

Indexed keywords

CASPASE 3; CASPASE 7; FLUOROURACIL; FORSKOLIN; MITOGEN ACTIVATED PROTEIN KINASE; OKADAIC ACID; OXALIPLATIN; PHOSPHOPROTEIN PHOSPHATASE 2A; PROTEIN KINASE B;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL LINE; CANCER INHIBITION; CANCER PATIENT; CELL GROWTH; CELL PROLIFERATION; CELL VIABILITY; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; FEMALE; HT 29 CELL LINE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; MALE; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; COMPARATIVE STUDY; ENZYME INHIBITION; PROTEIN PHOSPHORYLATION; VERY ELDERLY;

5-FLUOROURACIL; COLORECTAL CANCER; FORSKOLIN; OXALIPLATIN; PP2A-C PHOSPHORYLATION;

AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BLOTTING, WESTERN; CELL PROLIFERATION; COLFORSIN; COLORECTAL NEOPLASMS; ENZYME INHIBITORS; FEMALE; FLUOROURACIL; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; OKADAIC ACID; ORGANOPLATINUM COMPOUNDS; PHOSPHORYLATION; PROTEIN PHOSPHATASE 2; TUMOR CELLS, CULTURED; VASODILATOR AGENTS;

EID: 84904440789     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2014.06.032     Document Type: Article

References (26)

1. Walker A.S., Zwintscher N.P., Johnson E.K., et al. Future directions for monitoring treatment response in colorectal cancer. J. Cancer 2014, 5:44-57.
2. Siegel R., Desantis C., Jemal A. Colorectal cancer statistics. CA Cancer J. Clin. 2014, 64:104-117.
3. Dietvorst M.H., Eskens F.A. Current and novel treatment options for metastatic colorectal cancer: emphasis on aflibercept. Biol. Ther. 2013, 3:25-33.
4. Ewing I., Hurley J.J., Josephides E., Millar A. The molecular genetics of colorectal cancer. Frontline Gastroenterol. 2014, 5:26-30.
5. Hunter T. Protein kinases and phosphatases: the yin and yang of protein phosphorylation and signalling. Cell 1995, 80:225-236.
6. Eichhorn P.J., Creyghton M.P., Bernards R. Protein phosphatase 2A regulatory subunits and cancer. Biochim. Biophys. Acta 2009, 1795:1-15.
7. Janssens V., Goris J., Van Hoof C. PP2A: the expected tumor suppressor. Curr. Opin. Genet. Dev. 2005, 15:34-41.
8. Mumby M. PP2A: unveiling a reluctant tumor suppressor. Cell 2007, 130:21-24.
9. Westermarck J., Hahn W.C. Multiple pathways regulated by the tumor suppressor PP2A in transformation. Trends Mol. Med. 2008, 14:152-160.
10. Chen J., Martin B.L., Brautigan D.L. Regulation of protein serine-threonine phosphatase type-2A by tyrosine phosphorylation. Science 1992, 257:1261-1264.
11. Cristobal I., Blanco F.J., Garcia-Orti L., et al. SETBP1 overexpression is a novel leukemogenic mechanism that predicts adverse outcome in elderly patients with acute myeloid leukemia. Blood 2010, 115:615-625.
12. Cristobal I., Garcia-Orti L., Cirauqui C., Alonso M.M., Calasanz M.J., Odero M.D. PP2A impaired activity is a common event in acute myeloid leukemia and its activation by forskolin has a potent anti-leukemic effect. Leukemia 2011, 25:606-614.
13. Perrotti D., Neviani P. Protein phosphatase 2A (PP2A), a drugable tumor suppressor in Ph1(+) leukemias. Cancer Metastasis Rev. 2008, 27:159-168.
14. Kalev P., Sablina A.A. Protein phosphatase 2A as a potential target for anticancer therapy. Anticancer Agents Med. Chem. 2011, 11:38-46.
15. Perrotti D., Neviani P. Protein phosphatise 2A: a target for anticancer therapy. Lancet Oncol. 2013, 14:e229-e238.
16. Wang S.S., Esplin E.D., Li J.L., et al. Alterations of the PPP2R1B gene in human lung and colon cancer. Science 1998, 282:284-287.
17. Takagi Y., Futamura M., Yamaguchi K., Aoki S., Takahashi T., Saji S. Alterations of the PPP2R1B gene located at 11q23 in human colorectal cancers. Gut 2000, 47:268-271.
18. Ruediger R., Pham H.T., Walter G. Alterations in protein phosphatase 2A subunit interaction in human carcinomas of the lung and colon with mutations in the A beta subunit gene. Oncogene 2001, 20:1892-1899.
19. Tamaki M., Goi T., Hirono Y., Katayama K., Yamaguchi A. PPP2R1B gene alterations inhibit interaction of PP2A-Abeta and PP2A-C proteins in colorectal cancers. Oncol. Rep. 2004, 11:655-659.
20. Cristóbal I., Manso R., Rincón R., et al. PP2A inhibition is a common event in colorectal cancer and its restoration using FTY720 shows promising therapeutic potential. Mol. Cancer Ther. 2014, 13:938-947.
21. Tan J., Lee P.L., Li Z., et al. B55β-associated PP2A complex controls PDK1-directed myc signaling and modulates rapamycin sensitivity in colorectal cancer. Cancer Cell 2010, 18:459-471.
22. Lin S.P., Lee Y.T., Yang S.H., et al. Colon cancer stem cells resist antiangiogenesis therapy-induced apoptosis. Cancer Lett. 2012, 328:226-234.
23. Saydam G., Aydin H.H., Sahin F., et al. Involvement of protein phosphatase 2A in interferon-alpha-2b-induced apoptosis in K562 human chronic myelogenous leukaemia cells. Leuk. Res. 2003, 27:709-717.
24. Xiong Y., Jing X.P., Zhou X.W., et al. Zinc induces protein phosphatase 2A inactivation and tau hyperphosphorylation through Src dependent PP2A (tyrosine 307) phosphorylation. Neurobiol. Aging 2013, 34:745-756.
25. Gamet L., Murat J.C., Remaury A., et al. Vasoactive intestinal peptide and forskolin regulate proliferation of the HT29 human colon adenocarcinoma cell line. J. Cell. Physiol. 1992, 150:501-509.
26. Tsukamoto T., Hama S., Kogure K., Tsuchiya H. Selenate induces epithelial-mesenchymal transition in a carcinoma colorectal carcinoma cell line by AKT activation. Exp. Cell Res. 2013, 319:1913-1921.